Healthcare Sales & Marketing Network News: antihypertensive

Searching News Database: antihypertensive

HSMN NewsFeed - 8 Nov 2023
Recor Medical and Otsuka Medical Devices Announce First FDA-Approved Renal Denervation System for the Treatment of Hypertension
Devices Cardiology FDA

HSMN NewsFeed - 13 Jul 2022
SoniVie Announces successful procedure with TIVUS system on first patient enrolled for REDUCED1 Pilot study
Devices

HSMN NewsFeed - 13 Jun 2022
Ablative Solutions, Inc. Announces Completion of the Fourth Tranche of its Series D Preferred Financing Round for Unique Therapeutic Approach to Treating Uncontrolled Hypertension
Devices Venture Capital

HSMN NewsFeed - 1 Apr 2021
United Therapeutics Announces FDA Approval and Launch of Tyvaso(R) for the Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease
Biopharmaceuticals FDA Product Launch

HSMN NewsFeed - 9 Apr 2019
Alkermes Announces Positive Topline Results From Innovative Study of ARISTADA(R) and INVEGA SUSTENNA(R) for the Treatment of Schizophrenia
Biopharmaceuticals

HSMN NewsFeed - 27 Mar 2019
Novartis receives FDA approval for Mayzent(R) (siponimod), the first oral drug to treat secondary progressive MS with active disease
Biopharmaceuticals Neurology FDA

HSMN NewsFeed - 11 Oct 2018
Rigel Receives EMA Validation of the Marketing Authorization Application for Fostamatinib Disodium Hexahydrate in Chronic Immune Thrombocytopenia (ITP) in Adult Patients
Biopharmaceuticals Regulatory

HSMN NewsFeed - 8 Aug 2018
United Therapeutics Announces FREEDOM-EV Study Of Orenitram Meets Primary Endpoint
Biopharmaceuticals

HSMN NewsFeed - 29 May 2018
Egalet Announces Large Regional Plan to Cover SPRIX(R) Nasal Spray
Biopharmaceuticals Reimbursement

HSMN NewsFeed - 19 Jan 2018
Independent Imaging Review Confirmed Positive Data from Primary Analysis of REFLECT Trial Evaluating Lenvatinib Compared to Sorafenib in Unresectable Hepatocellular Carcinoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 29 Dec 2017
Progenics Pharmaceuticals Announces FDA Acceptance of New Drug Application for AZEDRA(R) (iobenguane I 131) in Pheochromocytoma and Paraganglioma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 15 Nov 2017
Noden Pharma Announces FDA Approval of Tekturna(R) (aliskiren) Oral Pellets for the Treatment of Hypertension in Adults and Children 6 Years of Age and Older
Biopharmaceuticals Cardiology FDA

HSMN NewsFeed - 5 Jun 2017
New Data Presented at ASCO 2017 Finds IMBRUVICA(R) (ibrutinib) May Offer a More Targeted Approach to Chronic Lymphocytic Leukemia (CLL) Treatment than Chemotherapy Agent Chlorambucil in Treatment-Naïve Patients
Biopharmaceuticals Oncology

HSMN NewsFeed - 31 May 2017
Lilly Announces Phase 3 RANGE Urothelial Cancer Trial of CYRAMZA(R) (ramucirumab) Met Primary Endpoint, Improving Progression-Free Survival
Biopharmaceuticals Oncology

HSMN NewsFeed - 19 Jan 2017
U.S. FDA Approves IMBRUVICA(R) (ibrutinib) as First Treatment Specifically Indicated for Relapsed/Refractory Marginal Zone Lymphoma (MZL) - a Rare Type of Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 31 Oct 2016
ReCor Medical Announces Key Milestones in RADIANCE-HTN Hypertension Clinical Study
Devices Cardiology

HSMN NewsFeed - 10 Oct 2016
First Positive Phase 3 Results in Adjuvant Setting for Renal Cell Carcinoma Show SUTENT(R) (sunitinib) Extended Disease Free Survival After Surgical Removal
Biopharmaceuticals Oncology

HSMN NewsFeed - 26 Sep 2016
AbbVie Announces Submission of a Supplemental New Drug Application for Ibrutinib (IMBRUVICA(R)) for Treatment of Marginal Zone Lymphoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 29 Jun 2016
AbbVie Announces Fourth Breakthrough Therapy Designation Granted by the U.S. Food and Drug Administration (FDA) for Ibrutinib (IMBRUVICA(R)) for Chronic Graft-Versus-Host-Disease (cGVHD), a Rare Condition with Limited Treatment Options
Biopharmaceuticals

HSMN NewsFeed - 6 Jun 2016
Allergan Announces FDA Approval of BYVALSON(TM) (nebivolol and valsartan)
Biopharmaceuticals Cardiology FDA

HSMN NewsFeed - 9 May 2016
U.S. FDA Expands IMBRUVICA(R) (ibrutinib) Label to Include Overall Survival Data in Previously Untreated Chronic Lymphocytic Leukemia (CLL) and New Indication for Small Lymphocytic Lymphoma (SLL) Patients
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 4 Apr 2016
ANI Pharmaceuticals Closes Acquisition of Inderal(R) LA Assets
Biopharmaceuticals Cardiology Acquisitions

HSMN NewsFeed - 16 Feb 2016
VIVLODEX(TM) Now Available in U.S. Pharmacies for the Management of Osteoarthritis Pain
Biopharmaceuticals Product Launch

HSMN NewsFeed - 6 Jan 2016
Vascular Dynamics’ MobiusHD(TM) System Receives CE Mark for the Treatment of Resistant Hypertension
Devices Cardiology Regulatory

HSMN NewsFeed - 23 Oct 2015
Iroko Pharmaceuticals Receives FDA Approval for VIVLODEX(TM) - First Low Dose SoluMatrix(R) Meloxicam for Osteoarthritis Pain
Biopharmaceuticals FDA

HSMN NewsFeed - 20 Aug 2015
Jardiance(R) Demonstrated Cardiovascular (CV) Risk Reduction in People with Type 2 Diabetes at High Risk for CV Events
Biopharmaceuticals Endocrinology

HSMN NewsFeed - 18 Dec 2014
The Medicines Company and SciClone Pharmaceuticals Establish Strategic Partnership for Two Cardiovascular Products in China
Biopharmaceuticals Cardiology Licensing

HSMN NewsFeed - 23 Sep 2014
Ivantis Raises Additional $25 MM, Increasing Series B to $71 MM
Devices Ophthalmology Venture Capital

HSMN NewsFeed - 25 Jul 2014
Bayer and Onyx Pharmaceuticals Report Phase 3 Trial Results of NEXAVAR(R) (sorafenib) in Patients with Advanced Breast Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 11 Jun 2014
Lilly Announces Top-Line Results Of Phase III Hepatocellular Carcinoma Trial
Biopharmaceuticals Oncology

HSMN NewsFeed - 22 May 2014
Preliminary Results From the St. Jude Medical EnligHTN III Study Demonstrate Renal Denervation Is Safe and Effective
Devices Cardiology

HSMN NewsFeed - 3 Jan 2014
Iroko’s ZORVOLEX(TM) Now Available
Biopharmaceuticals Product Launch

HSMN NewsFeed - 18 Dec 2013
Medtronic Randomizes First Patients in SYMPLICITY HTN-4, the First U.S. Renal Denervation Clinical Study for Patients with Moderate Uncontrolled Hypertension
Devices Interventional Cardiology

HSMN NewsFeed - 5 Dec 2013
Medtronic Announces CE Mark and TGA Listing for the Symplicity Spyral(TM) Multi-Electrode Catheter and Symplicity G3(TM) Generator
Devices Interventional Cardiology Regulatory

HSMN NewsFeed - 4 Jun 2013
St. Jude Medical Initiates First US Clinical Study of the EnligHTN Renal Denervation System for Drug-Resistant High Blood Pressure
Devices Cardiology Interventional

HSMN NewsFeed - 23 May 2013
One Year Data from St. Jude Medical Study Demonstrates Safe, Rapid and Sustained Blood Pressure Reduction with EnligHTN Renal Denervation Technology
Devices Cardiology

HSMN NewsFeed - 14 May 2013
St. Jude Medical Announces First Patient Enrollment in EnligHTN III Renal Denervation Study of Next-Generation EnligHTN System
Devices Interventional Cardiology

HSMN NewsFeed - 22 Mar 2013
FDA Approves GE Healthcare's AdreView(TM) (Iobenguane I 123 Injection) for Cardiac Risk Evaluation in Heart Failure Patients
Biopharmaceuticals Cardiology Radiology FDA

HSMN NewsFeed - 28 Aug 2012
Renal Denervation Technology from St. Jude Medical Demonstrates Safe, Rapid and Sustained Reduction in Blood Pressure
Devices Cardiology

HSMN NewsFeed - 29 Jun 2012
Actelion Pharmaceuticals Announces U.S. Food and Drug Administration Approval of Supplemental New Drug Application for Second Generation VELETRI(R) (epoprostenol) for Injection
Biopharmaceuticals FDA

HSMN NewsFeed - 16 May 2012
Renal Denervation Technology from St. Jude Medical Demonstrates Significant Reduction in Blood Pressure
Devices Cardiology

HSMN NewsFeed - 27 Apr 2012
Trial of Medtronic Symplicity(TM) Renal Denervation System Shows Significant Blood Pressure Reduction, With No Evidence of Renal Impairment, at Six Months Post Treatment
Devices Interventional Cardiology

HSMN NewsFeed - 11 Apr 2012
MacuCLEAR, Inc. To Begin Phase III Study of its Lead Compound for Early-Stage Age-Related Macular Degeneration (AMD)
Biopharmaceuticals Ophthalmology

HSMN NewsFeed - 27 Jan 2012
U.S. Food And Drug Administration Approves Pfizer’s INLYTA(R) (axitinib) For Patients With Previously Treated Advanced Renal Cell Carcinoma (RCC)
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 20 May 2011
SUTENT(R) Receives U.S. FDA Approval For Advanced Pancreatic Neuroendocrine Tumors
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 25 Apr 2011
Horizon Pharma Announces FDA Approval of DUEXIS(R) (ibuprofen/famotidine) for the Relief of the Signs and Symptoms of Rheumatoid Arthritis and Osteoarthritis and to Decrease the Risk of Developing Upper Gastrointestinal Ulcers
Biopharmaceuticals FDA

HSMN NewsFeed - 24 Mar 2011
Qualitest Receives FDA Approval for Toresmide Tablets (Generic Demadex(R)) 5 mg, 10 mg, 20 mg, 100 mg, for the Treatment of Edema Associated with Congestive Heart Failure, Renal Disease, or Hepatic Disease
Biopharmaceuticals Generics FDA

HSMN NewsFeed - 28 Feb 2011
FDA Approves INTUNIV(R) (guanfacine) Extended-Release Tablets for Use as Adjunctive Therapy to Stimulants for the Treatment of ADHD in Children and Adolescents
Biopharmaceuticals FDA

HSMN NewsFeed - 11 Jan 2011
NextWave Pharmaceuticals Secures $45 Million in Financing
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 22 Dec 2010
Corcept Therapeutics Announces Positive Phase 3 Study Results for CORLUX for the Treatment of Cushing's Syndrome
Biopharmaceuticals

HSMN NewsFeed - 2 Dec 2010
SUTENT(R) Receives European Approval for a New Indication in Progressive Pancreatic Neuroendocrine Tumors (NET)
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 15 Nov 2010
Santarus Announces Commercial Launch of Novel Type 2 Diabetes Drug CYCLOSET
Biopharmaceuticals Endocrinology

HSMN NewsFeed - 15 Oct 2010
Mylan Receives Approvals for Generic Versions of Hyzaar(R) and Cozaar(R)
Biopharmaceuticals Generics FDA

HSMN NewsFeed - 27 Sep 2010
Pfizer Discontinues Phase 3 Trial of SUTENT(R) in Advanced Castration-Resistant Prostate Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 27 Aug 2010
Novartis receives FDA approval of Tekamlo, a single-pill combination of aliskiren and amlodipine to treat high blood pressure
Biopharmaceuticals Cardiology FDA

HSMN NewsFeed - 26 Jul 2010
FDA Approves Tribenzor, A New Three-In-One Combination Product for the Treatment of High Blood Pressure
Biopharmaceuticals FDA

HSMN NewsFeed - 28 Jun 2010
New Data Shows Investigational Triple Antihypertensive Combination Therapy Significantly Lowers Blood Pressure in Hard-to-Treat Patients with Hypertension and Diabetes
Biopharmaceuticals

HSMN NewsFeed - 21 Jun 2010
New Head-to-Head Phase 3 Study Evaluated Systolic Blood Pressure Reduction of Investigational Compound Azilsartan Medoxomil Compared to Valsartan
Biopharmaceuticals Cardiology

HSMN NewsFeed - 3 May 2010
FDA Approved VIMOVO(TM) for Arthritis Patients at Risk of Developing NSAID-Associated Gastric Ulcers
Biopharmaceuticals Drug Delivery FDA

HSMN NewsFeed - 7 Apr 2010
Teva Announces Final Approval of Generic Hyzaar(R) and Cozaar(R)
Biopharmaceuticals Generics Cardiology FDA

HSMN NewsFeed - 2 Mar 2010
Teva Announces Favorable Court Ruling in Generic Hyzaar(R) and Cozaar(R) Litigation
Biopharmaceuticals Litigation Generics Cardiology

HSMN NewsFeed - 11 Feb 2010
FDA Approves Benicar(R) for the Treatment of High Blood Pressure in Children and Adolescents aged 6-16
Biopharmaceuticals Cardiology FDA

HSMN NewsFeed - 29 Jan 2010
Teva UK Limited Launches Lercanidipine Hydrochloride Film-Coated Tablets
Biopharmaceuticals Generics

HSMN NewsFeed - 22 Jan 2010
Data Show Progression-Free Survival Advantage with Sutent(R) in Patients with Pancreatic Neuroendocrine Tumors
Biopharmaceuticals Oncology

HSMN NewsFeed - 11 Jan 2010
Interim Study Data Indicate Improved Blood Pressure Management With Cardene(R) I.V. Compared to Labetalol in Patients with Acute Stoke
Biopharmaceuticals Cardiology Neurology

HSMN NewsFeed - 19 Oct 2009
FDA Approves New Use for Micardis(R) in Cardiovascular Risk Reduction and Twynsta(R) as New Combination Treatment for High Blood Pressure
Biopharmaceuticals Cardiology FDA

HSMN NewsFeed - 3 Sep 2009
Shire Announces FDA Approval of Once-Daily INTUNIV(TM) (guanfacine) Extended Release Tablets for the Treatment of ADHD in Children and Adolescents Aged 6 to 17
Biopharmaceuticals FDA

HSMN NewsFeed - 18 Aug 2009
Par Pharmaceutical & Aveva Drug Delivery Systems Receive Final Approval to Market Generic Catapres TTS(R)
Biopharmaceuticals Generics FDA

HSMN NewsFeed - 21 Jul 2009
FDA Approves Tekturna HCT(R) as Initial Treatment in Patients Unlikely to Achieve Their Blood Pressure Goals With a Single Agent
Biopharmaceuticals FDA

HSMN NewsFeed - 25 Jun 2009
Sutent Significantly Improved Progression-Free Survival for Patients with Advanced Pancreatic Islet Cell Tumors
Biopharmaceuticals Oncology

HSMN NewsFeed - 1 Jun 2009
Pfizer Discontinues SUN 1094 Trial of Sunitinib plus Paclitaxel in Advanced Breast Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 18 May 2009
AstraZeneca Announces TOPROL-XL(R) (Metoprolol Succinate) is Now Available
Biopharmaceuticals

HSMN NewsFeed - 13 May 2009
AZOR(R) Receives FDA Approval as First-Line Treatment for High Blood Pressure
Biopharmaceuticals FDA

HSMN NewsFeed - 8 May 2009
New Data Shows Blood Pressure Reduction Therapy With BENICAR(R) and BENICAR HCT(R) Effectively Reduces Blood Pressure in Elderly Patients to Target Blood Pressure
Biopharmaceuticals

HSMN NewsFeed - 8 May 2009
New Data Shows AZOR(R) (Amlodipine and Olmesartan Medoxomil) Significantly Improves 24-Hour Ambulatory Blood Pressure
Biopharmaceuticals Cardiology

HSMN NewsFeed - 2 Apr 2009
Pfizer Discontinues One Sunitinib Phase 3 Trial in Advanced Breast Cancer; Other Advanced Breast Cancer Trials Continue
Biopharmaceuticals Oncology

HSMN NewsFeed - 12 Mar 2009
Sutent Significantly Increases Progression Free Survival for Patients with Advanced Pancreatic Islet Cell Tumors, Study Stopped Early
Biopharmaceuticals Oncology

HSMN NewsFeed - 3 Feb 2009
Pfizer's Sutent is Recommended as First-Line Treatment for Kidney Cancer Patients by British Health Agency
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 28 Jan 2009
Ipsen announces the signature of a co-promotion agreement with Novartis for Exforge in France
Biopharmaceuticals

HSMN NewsFeed - 26 Aug 2008
New Publication Shows Cleviprex(TM) is Safe and Effective for Treatment of Acute, Severe Hypertension
Biopharmaceuticals

HSMN NewsFeed - 15 Aug 2008
Meda Acquires Product Portfolio from Roche
Biopharmaceuticals Acquisitions

HSMN NewsFeed - 4 Aug 2008
The Medicines Company's Cleviprex(TM) Receives FDA Approval
Biopharmaceuticals FDA

HSMN NewsFeed - 28 Jul 2008
Mylan Launches First Generic Version of Antihypertensive Sular(R) ER in the United States
Biopharmaceuticals Generics FDA

HSMN NewsFeed - 14 Jul 2008
New Publication Shows Cleviprex(TM) is Effective for Rapid Treatment of Acute Hypertension After Cardiac Surgery
Biopharmaceuticals Cardiology

HSMN NewsFeed - 20 Jun 2008
Controlling Perioperative Hypertension with Cleviprex Reduces Risk of Heart Attack and of Death Following Cardiac Surgery, According to New Analyses
Biopharmaceuticals Cardiology

HSMN NewsFeed - 18 Jun 2008
Two-Year Clinical Trial Findings Show Significant and Persistent Reduction in Blood Pressure with CVRx(R) Rheos(R) Hypertension Therapy
Devices

HSMN NewsFeed - 16 Jun 2008
Mylan Announces Tentative FDA Approval for Generic Version of Antihypertensive Avalide(R) Tablets
Biopharmaceuticals Generics FDA

HSMN NewsFeed - 16 Jun 2008
New Study Shows BENICAR(R) (olmesartan medoxomil) Reverses Blood Vessel Damage Independent of Blood Pressure Lowering
Biopharmaceuticals

HSMN NewsFeed - 15 May 2008
Landmark ATHENA Study Findings With Multaq(R)(dronedarone) Show 24% Reduction in Cardiovascular Hospitalisation or Death in Patients With Atrial Fibrillation
Biopharmaceuticals Cardiology

HSMN NewsFeed - 15 May 2008
KV Pharmaceutical Company Announces Approval for the 50 mg Strength of Generic Version of Toprol-XL(R)
Biopharmaceuticals Generics FDA

HSMN NewsFeed - 15 May 2008
Stable Stroke Patients More Likely to Die From a Nonstroke Cardiovascular Event Than a Further Stroke
Neurology

HSMN NewsFeed - 14 May 2008
New Data Shows 45 Percent of Patients With Stage 1 Hypertension Reached Normotension With BENICAR(R) and BENICAR HCT(R)
Biopharmaceuticals

HSMN NewsFeed - 12 May 2008
Forest Laboratories, Inc. and Daiichi Sankyo, Inc. Announce the Termination of the AZOR Co-Promotion Agreement
Biopharmaceuticals

HSMN NewsFeed - 1 May 2008
Coversyl(R) Protects Hypertensive Patients Against New-Onset Diabetes
Biopharmaceuticals

HSMN NewsFeed - 31 Mar 2008
Landmark Trial ONTARGET(R) Proves Telmisartan is as Protective as Ramipril and Better Tolerated in a Broad High-Risk Cardiovascular Population. From ONTARGET(R) it May be Concluded That Telmisartan can Prevent Every 5th Serious Cardiovascular Event
Biopharmaceuticals Cardiology

HSMN NewsFeed - 31 Mar 2008
Lotrel, a Single-Pill Combination for Treating High Blood Pressure, Reduced Cardiovascular Events by 20% in High-Risk Patients
Biopharmaceuticals Cardiology

HSMN NewsFeed - 21 Jan 2008
US Approval for SPP100 Combined with Diuretic to Treat Hypertension
Biopharmaceuticals FDA

HSMN NewsFeed - 7 Jan 2008
James Ferguson, MD Joins The Medicines Company as Vice President, Global Medical, Surgical and Critical Care
Biopharmaceuticals Personnel

HSMN NewsFeed - 19 Nov 2007
Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve BP Goals
Biopharmaceuticals Cardiology FDA

HSMN NewsFeed - 7 Nov 2007
Axiom Worldwide's International Medical Advisory Board Steering Committee Issues Consensus Statement Regarding the Axiom Protocols!
Devices Neurosurgery Orthopaedic

HSMN NewsFeed - 23 Oct 2007
Cleviprex(TM) (Clevidipine Butyrate) Rapidly Reduced Blood Pressure and Maintained Control in Study of Patients with Acute Hypertension
Biopharmaceuticals Cardiology

HSMN NewsFeed - 15 Oct 2007
Improved Perioperative Blood Pressure Control Associated with Reduced Risk of Kidney Dysfunction in Cardiac Surgery Patients
Biopharmaceuticals Cardiology Surgery

HSMN NewsFeed - 27 Sep 2007
AZOR(TM) Receives FDA Approval for Treatment of High Blood Pressure
Biopharmaceuticals FDA

HSMN NewsFeed - 14 Sep 2007
FDA Accepts NDA Filing for Cleviprex(TM) (Clevidipine Butyrate Injectable Emulsion) for the Treatment of Acute Hypertension
Biopharmaceuticals

HSMN NewsFeed - 6 Sep 2007
Ranbaxy Gains Approval to Manufacture and Market Carvedilol Tablets in the U.S. Market
Biopharmaceuticals Cardiology Generics FDA

HSMN NewsFeed - 6 Sep 2007
Pfizer Oncology Initiates Global Phase III Trial to Evaluate Sunitinib Malate Combined with Erlotinib in Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 5 Sep 2007
REACH Registry Highlights That Patients With Peripheral Arterial Disease (PAD) Suffer High Rates of Heart Attack, Stroke, Hospitalization, and Death
Cardiology

HSMN NewsFeed - 21 Aug 2007
Daiichi Sankyo and Forest Laboratories Sign Letter of Intent for Co-Promotion of AZOR(TM)
Biopharmaceuticals

HSMN NewsFeed - 10 Jul 2007
Ranbaxy Receives Final Approval To Manufacture and Market Amlodipine Besylate Tablets
Biopharmaceuticals Generics FDA

HSMN NewsFeed - 2 Jul 2007
NicOx appoints Pascal Pfister MD as Chief Scientific Officer and strengthens R&D organization
Biopharmaceuticals Personnel

HSMN NewsFeed - 20 Jun 2007
Ranbaxy Receives Tentative Approval to Manufacture and Market Amlodipine Besylate Tablets
Biopharmaceuticals Generics FDA

HSMN NewsFeed - 13 Jun 2007
CardioDynamics Announces New ICG Hypertension Evidence
Devices Monitoring Cardiology

HSMN NewsFeed - 3 Jun 2007
Single-Agent SUTENT Prolonged Progression-Free Survival across All Advanced Kidney Cancer Patient Risk Groups, Including Those with Poorest Prognoses, Data Show
Biopharmaceuticals Oncology

HSMN NewsFeed - 2 Jun 2007
New Data Evaluating SUTENT, CP-751,871 and Axitinib in Patients with Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 23 May 2007
Arete Therapeutics Raises $35 Million
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 21 May 2007
BENICAR HCT(R) Reductions in Seated Systolic Blood Pressure for Stage 2 Patients Compared With Amlodipine + Benazepril
Biopharmaceuticals Cardiology

HSMN NewsFeed - 21 May 2007
Data Presented at ASH Demonstrate Nebivolol Lowers Blood Pressure as Long-Term Monotherapy and in Combination Therapy
Biopharmaceuticals Cardiology

HSMN NewsFeed - 21 May 2007
Amlodipine and Olmesartan Study Results Released; Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
Biopharmaceuticals Cardiology

HSMN NewsFeed - 18 May 2007
KV Pharmaceutical Company Announces Approval for Two Strengths of Generic Versions of Toprol-XL(R)
Biopharmaceuticals Generics FDA

HSMN NewsFeed - 27 Mar 2007
Pivotal Phase III Findings With Investigational Drug Cleviprex(TM) (Clevidipine) Demonstrate Perioperative Blood Pressure Control In Cardiac Surgery
Biopharmaceuticals Cardiology

HSMN NewsFeed - 27 Mar 2007
Landmark Findings From ECLIPSE Program Show Improved Control of Perioperative Hypertension Reduces Risk of Death In Cardiac Surgery
Biopharmaceuticals Cardiology

HSMN NewsFeed - 28 Feb 2007
Hana Biosciences Appoints Lyn Wiesinger to Board of Directors
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 8 Feb 2007
Pfizer's Sutent Receives FDA Approval to Include New First-Line Advanced Kidney Cancer Data in Label
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 4 Jan 2007
AVEO Acquires Clinical Stage Anti-Cancer Compound From Kirin
Biopharmaceuticals Oncology Licensing

HSMN NewsFeed - 2 Jan 2007
Ranbaxy Granted Final U.S. FDA Approval to Manufacture and Market Atenolol Tablets
Biopharmaceuticals Generics FDA

HSMN NewsFeed - 22 Dec 2006
Exforge(R) Receives US Regulatory Approval as a New and Highly Effective Treatment Option for Patients with High Blood Pressure
Biopharmaceuticals FDA

HSMN NewsFeed - 21 Nov 2006
Par Pharmaceutical Begins Shipment of Generic TOPROL-XL(R)
Biopharmaceuticals Generics Distribution

HSMN NewsFeed - 8 Nov 2006
diaDexus Reports Study Showing Lp-PLA2 Is an Independent Marker of Coronary Artery Disease and Death
Diagnostics Cardiology

HSMN NewsFeed - 27 Oct 2006
NicOx Naproxcinod Phase 3 OA Trial Meets Primary Endpoints and Shows Encouraging Blood Pressure Profile
Biopharmaceuticals

HSMN NewsFeed - 2 Oct 2006
Plexxikon and Servier Signed Cardiovascular Collaboration
Biopharmaceuticals

HSMN NewsFeed - 21 Sep 2006
Ranbaxy Receives Approval to Commercialize Furosemide Tablets in the U.S.
Biopharmaceuticals Generics FDA

HSMN NewsFeed - 15 Sep 2006
King Pharmaceuticals Reports DREAM Data on Ramipril
Biopharmaceuticals Cardiology

HSMN NewsFeed - 13 Sep 2006
FibroGen Appoints Melissa L. Grigorieff, Vice President of Marketing
Biopharmaceuticals Personnel

HSMN NewsFeed - 11 Sep 2006
The Medicines Company Completes Clevidipine Phase III Safety Trials and Initiates Phase III Severe Hypertension Trial
Biopharmaceuticals Cardiology

HSMN NewsFeed - 6 Sep 2006
Amlodipine Based Regimen to Lower Blood Pressure, Reduces the Risk of New-Onset Diabetes in Hypertensive Patients by More Than a Third
Biopharmaceuticals Cardiology

HSMN NewsFeed - 6 Jul 2006
King Pharmaceuticals and Wyeth Announce Restructuring of Co-Promotion Agreement for ALTACE(R)
Biopharmaceuticals

HSMN NewsFeed - 28 May 2006
Teva Announces Tentative Approval for Generic Cozaar(R) Tablets
Biopharmaceuticals Generics FDA

HSMN NewsFeed - 17 May 2006
New Data Show COREG CR (TM) Reduced Blood Pressure in Patients With Essential Hypertension
Biopharmaceuticals Cardiology

HSMN NewsFeed - 17 May 2006
New Phase III Data on Renin Inhibitor SPP100 (Rasilez) in Treatment of Hypertension Demonstrates Potential of This First-in-Class Drug
Biopharmaceuticals

Return to NewsFeed

Additional items found! 92

Members: click here for search results from The HSMN Archive (password required)

Members Archive contains 92 additional stories matching:
antihypertensive
(Password required)

FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.

RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!